Home › Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer
 

Keywords :   


Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer

2013-09-11 09:15:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. & LONDON WHITEHOUSE STATION, N.J. & LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Mercks oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer. Language: English Contact: MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for enter agreement license

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 2
29.06Tropical Storm Beryl Public Advisory Number 2
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 2
29.06Tropical Storm Beryl Forecast Advisory Number 2
More »